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Background: Pericardiocentesis for collections causing pericardial tamponade con-
tinues to be frequently performed in cath lab, more so due to the complexity of lesions
and hardware in use currently.
Methods: We attempted to analyse the etiology of serial cases requiring pericardial
ﬂuid aspiration between 2001 to 2013 at our Institute, a premier tertiary care referral
centre in South India.
Results: Emergent Pericardiocentesis has been done for 158 patients in the Cath lab
at our Institute between 2001 to 2013.Of the total 12500PTMCdone 43 patients( 0.03%)
have needed emergency pericardiocentesis for periprocedural pericardial effusion with
tamponade during balloon valvotomy, the most common cause being LA wire-induced
perforation. 7 patients subsequently needed emergency MVR also, for concomitant
AML leaﬂet tear and severe MR.5 patients (0.007%) undergoing pulmonary valve
balloon dilation needed pericardiocentesis for periprocedural pericardial tamponade. 4 of
these patients underwent successful balloon dilation and one had to be referred for
surgery. Post- surgical pericardial effusion had to be drained in 16 patients (7 post-
MVR,2 post CABG, 3 post- ASD repair, and 4 post-AVR). In 14 patients there was
suspected malignant etiology of the pericardial collection ( as seen on analysis of the
aspirate )and these were referred to specialist oncology institutes for management. 6
patients undergoing PTCA of total 6200 procedures (<0.1%) suffered pericardial tam-
ponade which had to be drained in cath lab immediately due to hemodynamic
compromise, all these patients underwent successful stenting subsequently. 4 patients
undergoing EPS study had to undergo pericardiocentesis – 3 had septal puncturewith left
sided pathway AVRT and one had RVOT-VT successfully ablated. The bulk of peri-
cardiocentesis was done for idiopathic/infective pericardial collections causing hemo-
dynamic effects of tamponade- 56 of the 158 (35.4 %)- most commonly of tubercular/
viral/pyogenic etiology. Three of these patients had recurrent collection despite Anti
Tuberculous therapy andunderwent second pericardocentesis. Therewas deﬁnite history
of hypothyroidism (or being treated for same) in 10 patients undergoing peri-
cardiocentesis. Constrictive pericarditis was diagnosed in 6 patients, who subsequently
underwent pericardiectomy and restrictive cardiomyopathy was diagnosed in 3 patients.
Conclusion: Collections of infective origin seem to be the commonest (w35%) cause at
our centre needing pericardiocentesis .Mitral valvotomy periprocedural effusions lead-
ing to tamponade still continues to be account for 0.03 % of total BMV procedures.
Though complex coronary procedures are performed at our centre, only< 0.1% needed
ﬂuid drainage for emergency tamponade. The etiology at any particular centre would
probably depend on the type of heart disease it primarily caters to, as in coronary cases
outnumbering rheumatic ones at certain hospitals and vice versa at other institutes.P
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Comparison of Short-term Clinical Outcomes with Prasugrel Versus Adjunctive
Cilostazol to Dual Anti-platelet Therapy in Patients with Acute Myocardial
Infarction Underwent Percutaneous Coronary Intervention
Keun-Ho Park, Myung Ho Jeong, Youngkeun Ahn, Ju Han Kim, Young Joon Hong,
Doo Sun Sim
Chonnam National University Hospital, Gwangju, Korea (Republic of)
Background: It has been well known that prasugrel and adjunctive cilostazol to dual
anti-platelet therapy (triple anti-platelet therapy; TAP) could improve the clinical
outcomes in patients with acute myocardial infarction (AMI) underwent percutaneous
coronary intervention (PCI). However, the data about comparison of clinical outcomes
between two groups were not available yet. Therefore, We compared the short-term
clinical outcomes between prasugrel and TAP in patients with AMI underwent PCI.
Methods: We analyzed 1,192 AMI patients underwent PCI with receiving Prasugrel
or TAP in iCReaT AMI registry from 15 centers in Korea between Jan. 2012 and Jun.
2013. Of these, 412 patient received the prasugrel and 780 patients did TAP during
hospitalization. Major adverse cardiovascular events (MACE) deﬁned as a composite
of cardiac death, MI, stroke or target vessel revascularization (TVR) and safety end-
point was Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding
during hospitalization.
Results: Mean age was lower (57.3710.19 years vs. 65.9912.25 years, p<0.001)
and creatinine clearance (93.7738.61 ml/min vs. 71.8438.72 ml/min, p<0.001)
was higher in prasugrel group than TAP group. Female gender (14.6% vs. 32.4%,
p<0.001), the history of hypertension (40.8% vs. 55.3%, p<0.001), diabetes (22.3%
vs. 35.6%, p<0.001) and previous cerebrovascular accidents (1.7% vs. 9.6%,
p<0.001) were more common in TAP group, however, prasugrel group was more
common in presented with STEMI (63.3% vs. 48.5%, p<0.001), current smoker
(55.6% vs. 34.9%, p<0.001) and the family history of coronary artery disease (8.7%JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/POSTvs. 5.1%, p¼0.015). P2Y12 reactivity unit by VerifyNow P2Y12 assay was signiﬁ-
cantly higher in prasugrel group than TAP group (138.60116.75 vs. 287.4384.40,
p<0.001). During hospitalization, there were no differences in the incidences of
cardiac death, MI, stroke and MACE between prasugrel and TAP group (1.9% vs.
2.1%, p¼0.898; 0.7% vs. 1.2%, p¼0.560; 0.5% vs. 1.2%, p¼0.348; 3.2% vs. 3.9%,
p¼0.543). Also, no differences in major and minor bleeding were observed (1.7% vs.
2.6%, p¼0.340; 2.2% vs. 3.5%, p¼0.220). Only 466 patients (39.1%) followed up at
6-month. The incidences of 6-month TVR and MACE were not also signiﬁcantly
different between two groups (2.2% vs. 1.3%, p¼0.631; 4.3% vs. 2.9%, p¼0.513).
Conclusion: Our study showed that prasugrelmay have similar safety and efﬁcacy toTAP
inpatientswithAMIunderwentPCI.However, further large and randomized trial should be
needed to accurately assess the clinical beneﬁt of prasugrel in Korean AMI patients.
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Response of Loading Dose & Follow-up of Prasugrel (PRISA) on Platelet
Aggregation in Coronary Artery Disease Patients Undergoing Percutaneous
Coronary Intervention
Ahmad Shahbaz1, Ahmad Nouman1, Khawar Mehdi2, Muhammad Azhar1
1PIC, Lahore, Pakistan, 2Getz Pharma, Karachi, Pakistan
Background: The use of dual antiplatelet therapy with aspirin and a thienopyridine in
coronary artery disease (CAD) is an essential aspect of a supportive pharmacologic
regimen administered to patients undergoing percutaneous coronary intervention
(PCI). Prasugrel, a thienopyridine reduces platelet aggregation and has been demon-
strated to improve outcomes in patients presenting with acute coronary syndrome.
This study was carried out to determine the effect of loading dose of prasugrel
(PRISA) on platelet aggregation in CAD patients undergoing PCI.
Methods: A total of 50 out of 120 CAD patients were screened as per inclusion
criteria (Both genders b/w the ages of 18 - 65 undergoing PCI) and participated in the
study. During PCI the Platelet aggregation inhibition tests were performed just before
and immediately after (3-4 hours) the loading dose of 60 mg Prasugrel with Chronolog
Whole Blood Aggregometer Model 591A/592A using ADP (Adenosine diphospahte)
reagent. Upon discharge the patients were maintained on 10 mg Prasugrel daily for 14
days. Platelet aggregation inhibition test was performed again at Day 14 and clinical
outcomes like minor & major bleeding, shortness of breath and death were observed.
SPSS version 17 was used to analyze the data.
Results: Male and female ratio was 4:1, mean age 50.3 +9.6 (range: 29 - 68 years).
The Risk factor history comprised of 60% hypertensive, 38% with family history of
CAD, 32% diabetic, 8% hyperlipidemic and 18% with MI history. Out of 40 males;
10% were smokers, 48% ex-smokers and 42% non smokers. The occurrence of CAD
was: LAD 25 (50%), RCA 14 (28%), Cx Distal 5 (10%), MVD 3 (6%), Non Stent 1
(2%) and others 2 (4%). The mean platelet aggregation (MPA) values before loading
dose, after loading dose and at 14 days follow-up were 6.08 +2.12 SD, 1.56 +2.11 SD
and 0.53 +1.37 SD respectively with statistically signiﬁcant (p<0.001) difference
showing good response to Prasugrel (PRISA). None of the patient suffered side effect
after the loading dose of prasugrel during PCI at 2 weeks follow-up.
Conclusion: Prasugrel (PRISA) was seen to be clinically effective, well tolerated &
safe with signiﬁcant MPA reduction after loading dose of prasugrel during PCI and at
14 days follow-up.
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Comparison of Original and Generic Enoxaparin for Treatment of Coronary
Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Kitigon Vichairuangthum, Paiboon Chotenoparatpat
Vajira Hospital, Bangkok, Thailand
Background: To compare the anti-factor Xa level and major adverse cardiac events
(MACE) in coronary artery disease patients undergoing percutaneous coronary
intervention who was treatment with original enoxaparin and generic enoxaparin.
Methods: This study is a randomized double blind controlled trial studied in coronary
artery disease patients (unstable angina, non-ST elevation myocardial infarction,
chronic stable angina) who underwent percutaneous coronary intervention in our
institute between January and August 2010. The coronary artery disease patients were
randomly assigned to receive either original or generic enoxaparin before the percu-
taneous coronary intervention. Anti-factor Xa level were measured before and at 1 and
4 hours after percutaneous coronary intervention. Major adverse cardiac events were
monitored during admission and at 3 month after the procedure.
Results: Thirty patients received generic enoxaparin, while 36 patients received
original enoxaparin. The mean age of the two groups were 65.5  5.5 and 64.2  4.5
years respectively. The baseline characteristics of two groups were comparable except
for type of stent. The drug eluting stents were used more in generic enoxaparin group
compared to original enoxaparin group (70.0% and 56.0%). There was no signiﬁcant
difference of anti-factor Xa level at 1 hour (1.20 vs 1.43; p-value ¼0.126) and 4 hours
(0.63 vs 0.67; p-value¼0.635) after the intervention between both groups. However,
in the generic enoxaparin group, there were 2 patients (6.7%) who had thrombus
formation during the intervention and there were 3 (10.0%) of major adverse cardiac
events (2 patients (6.7%) had nonfatal myocardial infarction and 1 patient (3.3%) had
repeat coronary revascularization), while in the original enoxaparin group, there were
no patients who had thrombus formation during the intervention (p-value ¼ 0.202)
and no one had major adverse cardiac events (p-value ¼ 0.089).
Conclusion: Anti-factor Xa level was not signiﬁcant different between those who
received generic or original enoxaparin. However, MACE tended to be higher in theER/Antiplatelet Agents and Anticoagulants S41
